Valentine Wanga

Valentine Wanga

Auto-generated profile, based on publicly available information

Valentine Wanga

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Biometrics
Verified
Journal Article
Closed access
PDF file
QLQi Liu
Qi Liu
CLChun Li
Chun Li
VWValentine Wanga
Valentine Wanga
BSBryan E. Shepherd
Bryan E. Shepherd

31 December 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
VWValentine Wanga
Valentine Wanga
This report describes outcomes of children and adolescents <18 Years Hospitalized with COVID-19.

10 September 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
VWValentine Wanga
Valentine Wanga
JCJennifer R. Chevinsky
Jennifer R. Chevinsky
LDLina V. Dimitrov
Lina V. Dimitrov
MGMegan E. Gerdes
Megan E. Gerdes
GWGeoffrey P. Whitfield
Geoffrey P. Whitfield
JCJennifer R. Cope
Jennifer R. Cope
This report describes the percentage of adults infected with COVID-19 who experience long-term symptoms.

1 October 2018 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
Linnet OngeriLinnet Ongeri
Linnet Ongeri
VWValentine Wanga
Valentine Wanga
POPhelgona Otieno
Phelgona Otieno
JMJane Mbui
Jane Mbui
EJElizabeth Juma
Elizabeth Juma
MMMuthoni Mathai
Muthoni Mathai
Few longitudinal studies have examined associations between risk factors during pregnancy and mental health outcomes during the postpartum period. We used a cohort study design to estimate the prevalence, incidence and correlates of significant postpartum depressive symptoms in Kenyan women. We recruited adult women residing in an urban, resource-poor setting and attending maternal and child health clinics in two public hospitals in Nairobi, Kenya. A translated Kiswahili Edinburgh Postpartum Depression Scale was used to screen for depressive symptoms at baseline assessment in the 3rd trimester and follow up assessment at 6–10 weeks postpartum. Information was collected on potential demographic, psychosocial and clinical risk variables. Potential risk factors for postpartum depression were evaluated using multivariate logistic regression analysis. Out of the 171 women who were followed up at 6–10 weeks postpartum, 18.7% (95% CI: 13.3–25.5) were found to have postpartum depression using an EPDS cut off of 10. In multivariate analyses, the odds of having postpartum depression was increased more than seven-fold in the presence of conflict with partner (OR = 7.52, 95% CI: 2.65–23.13). The association between antepartum and postpartum depression was quite strong but did not reach statistical significance (OR = 3.37, 95% CI: 0.98–11.64). The high prevalence of significant postnatal depressive symptoms among Kenyan women underscores the need for addressing this public health burden. Depression screening and psychosocial support interventions that address partner conflict resolution should be offered as part of maternal health care.

20 August 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
VWValentine Wanga
Valentine Wanga
VOVictor Omollo
Victor Omollo
EBElizabeth A Bukusi
Elizabeth A Bukusi
JOJosephine B Odoyo
Josephine B Odoyo
JMJennifer F Morton
Jennifer F Morton
JBJared M Baeten
Jared M Baeten
Introduction: HIV testing is a required part of delivery of pre‐exposure prophylaxis (PrEP) for HIV prevention. However, repeat testing can be challenging in busy, under‐staffed clinical settings, which could negatively impact PrEP uptake and continuation. We prospectively evaluated optional facility‐based HIV self‐testing (HIVST) among young women using PrEP in an implementation programme.Methods: Between February and November 2019, we collected data from young women receiving PrEP at two family planning facilities in Kisumu, Kenya. At each PrEP follow‐up visit, women were given the option to choose between provider‐initiated testing and HIVST. We assessed factors associated with HIVST uptake and compared satisfaction with HIV testing and clinic experience between acceptors and decliners of HIVST.Results: A total of 172 women were offered HIVST at 202 PrEP follow‐up visits. The median age was 21 years, 27% had multiple partners and 15% reported previously using HIVST. HIVST was accepted at 34.7% (70/202) of visits. Age (adjusted relative risk (aRR) 1.09 per year, 95% CI (confidence interval) 1.01 to 1.18), never being married (aRR 1.81, 95% CI 1.11 to 2.95) and having more PrEP follow‐up visits (aRR 1.13 per visit, 95% CI 1.04 to 1.23) were associated with HIVST uptake. Compared to HIVST decliners, HIVST acceptors were more likely to be very happy with their overall testing experience (73% vs. 47% of visits, p = 0.003) and were more likely to say they would use HIVST in the future (96% vs. 76%, p < 0.001). Women who accepted HIVST had shorter visits than those choosing standard provider‐initiated HIV testing (median [IQR]: 33 [32, 38] vs. 54 [41.5, 81] minutes, p = 0.003).Conclusions: In this pilot evaluation in Kenya, about one‐third of women using PrEP opted for HIVST over provider‐initiated testing, and those choosing HIVST spent less time in the clinic and were generally satisfied with their experience. HIVST in PrEP delivery is feasible and has the potential to simplify PrEP delivery and give clients testing autonomy. Additional studies are needed to explore optimal HIV retesting strategies in PrEP delivery, including the use of HIVST in PrEP at a larger scale and in different settings.

22 February 2015 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
JFJoshua Fuqua
Joshua Fuqua
VWValentine Wanga
Valentine Wanga
KPKenneth E. Palmer
Kenneth E. Palmer
Griffithsin is a broad spectrum antiviral lectin that inhibits viral entry and maturation processes through binding clusters of oligomannose glycans on viral envelope glycoproteins. An efficient, scaleable manufacturing process for griffithsin active pharmaceutical ingredient (API) is essential for particularly cost-sensitive products such as griffithsin -based topical microbicides for HIV-1 prevention in resource poor settings. Our previously published purification method used ceramic filtration followed by two chromatography steps, resulting in a protein recovery of 30%. Our objective was to develop a scalable purification method for griffithsin expressed in Nicotiana benthamiana plants that would increase yield, reduce production costs, and simplify manufacturing techniques. Considering the future need to transfer griffithsin manufacturing technology to resource poor areas, we chose to focus modifying the purification process, paying particular attention to introducing simple, low-cost, and scalable procedures such as use of temperature, pH, ion concentration, and filtration to enhance product recovery. We achieved >99% pure griffithsin API by generating the initial green juice extract in pH 4 buffer, heating the extract to 55°C, incubating overnight with a bentonite MgCl2 mixture, and final purification with Capto™ multimodal chromatography. Griffithsin extracted with this protocol maintains activity comparable to griffithsin purified by the previously published method and we are able to recover a substantially higher yield: 88 ± 5% of griffithsin from the initial extract. The method was scaled to produce gram quantities of griffithsin with high yields, low endotoxin levels, and low purification costs maintained. The methodology developed to purify griffithsin introduces and develops multiple tools for purification of recombinant proteins from plants at an industrial scale. These tools allow for robust cost-effective production and purification of griffithsin. The methodology can be readily scaled to the bench top or industry and process components can be used for purification of additional proteins based on biophysical characteristics.